Gilead Sciences has been looking for a win for Trodelvy after two surprise trial failures earlier this year. But it looks ...

When AstraZeneca’s Alexion picked up rare disease specialist Syntimmune in 2018 for $ | A Delaware judge agreed that ...

With the expiration of a contract to produce antibiotic medicines for Sandoz, GSK will shutter a 75-year-old manufacturing ...

BMS ran its first C2C4C event in 2014, when an employee worked with colleagues to put together a team of 53 oncology staffers ...

Three months on, Eli Lilly has closed the books on its search for a new chief financial officer. And as with its previous CFO ...

After opting out of Teva’s $4.25 billion national opioid settlement last year, the city of Baltimore has secured its own payout through a settlement deal worth $80 million. | The city scored its own ...

Why is PDA’s Universe of Pre-Filled Syringes and Injection Devices Conference the must-attend event of the year? Get an ...

The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. | ...

The Rybrevant-Lazcluze combo lowered the risk of death by 23% compared with Tagrisso in an updated analysis of the phase 3 ...

A year after missing on a trial endpoint, Travere Therapeutics can breathe a sigh a relief. | A year after missing on a trial ...

Novartis is investing more than $200 million to further bolster its radiotherapy infrastructure with a brand-new facility and ...

After years of documentation and industry neglect, the World Health Organization (WHO) issued its first-ever guidance aimed ...